ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Aug 16, 2017
Stocks with High Valuentum Buying Index Ratings and Strong Dividend Growth Prospects
Use this download to uncover stocks with high Valuentum Buying Index ratings and strong dividend growth prospects.
Aug 16, 2017
Stocks That Are Cheap on Both a DCF and Relative Value Basis
Use this download to uncover stocks that may be cheap on both a discounted cash-flow basis and relative value basis.
Aug 16, 2017
Dividend Yields to Consider Avoiding!
Image Source: Eugene Zemlyanskiy. Use this download to uncover the most risky dividends on the market.
Aug 14, 2017
Post-Earnings Update: AbbVie
Image Source: Global Panorama. AbbVie’s top-line performance has been relatively strong (unlike its big pharma peers), translating into a generous dividend--further enhancing the appeal of the equity. But are the company’s attractive fundamentals about to change? Let’s take a look at AbbVie’s fundamentals following its second-quarter report, released July 28.
Aug 11, 2017
Chicago Bridge's Troubles Continue
Image Source: Chicago Bridge & Iron. We've lowered our fair value estimate for Chicago Bridge & Iron.
Aug 9, 2017
North Korea and the Bomb
Image Source: James Vaughan. Tensions between the United States and North Korea have heightened, and we may look to August 2017 as the dawn of yet another Cold War. The news has little impact on our thesis, however. US stocks generally remain overvalued, and some of them considerably. In this note, let’s cover a few stocks in the news and reiterate our positive stance on the defense industry, two of our favorite ideas recently highlighted in the Nelson Exclusive publication. Learn more about the Nelson Exclusive publication here.
Aug 8, 2017
Discovery-Scripps Joining Forces to Take on the Changing Digital Media Landscape
Image Source: Lwp Kommunikáció. Discovery Communications has agreed to acquire Scripps Networks, but will it be enough for the two to remain competitive in the rapidly evolving--and consolidating--media landscape?
Aug 7, 2017
Generic Drug Price Deflation Continues to Weigh on Shares of Teva
Shares of former Best Ideas Newsletter portfolio idea Teva Pharmaceuticals have come under renewed selling pressure after reporting weak quarterly results due largely to deflationary price pressures felt in the generic drug division. Teva has been relatively powerless in stopping the trend. We had removed the shares from the Best Ideas Newsletter portfolio well before the last leg down, and the Dividend Cushion ratio warned of tremendous risk to the sustainability of the dividend far in advance.
Aug 7, 2017
Bioverativ: A Profitable Rare Drug Company
Image Source: Bioverativ. The biotech sector remains one of the most innovative segments of the overall market. Cutting-edge research is being conducted to help treat a wide swath of disease states with the potential for outsize rewards if the novel treatment is proven effective. The boom-bust nature of clinical research has lead to numerous spectacular flameouts, which lessen the appeal of the sector to the more risk-averse investor. We have identified a promising newly-formed company with real earnings, and one that may be poised to accelerate earnings now that a promising new rare-disease molecule has been brought into the fold.
Aug 7, 2017
Understanding How Dividends Impact Intrinsic Value Estimation
"Dividends are a transfer of cash to the shareholders that the shareholders owned anyway." -- Brian Nelson, CFA. In this purely educational article, let’s walk through how dividends impact the intrinsic value of a company.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.